Anti-inflammatory Treatment for Inactive Takayasu Arteritis
Status:
Unknown status
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Currently, the traditional disease activity of Takayasu arteritis is mainly based on National
Institutes of Health criteria and the inactive cases don't need anti-inflammatory treatment.
However, pathologic findings showed that there was still inflammatory activity in the
affected vessels, and the follow-up data also found significant lesion progression in some
inactive cases. Sixty inactive Takayasu arteritis patients will be recruited to determine
whether these individuals are active by screening new inflammatory markers in this study. New
inflammatory markers included tumor necrosis
factor,interleukin-2,interleukin-6,interleukin-8,interleukin-10,high-sensitivity C-reactive
protein, and 18f-FDG positron emission tomograph. According to new inflammatory markers,
sixty patients will be divided into two categories: inactive patients (n=20) and active
patients (n=40). And then, Forty active patients diagnosed by new inflammatory markers will
be randomly assigned to either anti-inflammatory therapy group or control group. The changes
of inflammatory activity and lesion progression will be observed during one-year follow up in
all 60 patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital